A 2022 yearlong initiative at Summa Health Cancer Institute saw 100% of its patients with head and neck cancer undergoing radiation treatment referred to an oncology dietician for nutritional support and/or speech and swallow therapy.
Joelle Hicks, BSN, RN, Summa Health Cancer Institute
Between January 1 and December 31, 2022, 100% of patients with head and neck cancer undergoing radiation treatment at Summa Health Cancer Institute in Ohio were referred to an oncology dietician to receive ongoing nutritional support plus speech and swallow therapy to manage the adverse effects (AEs) of their treatment over the long term. Timely access to an outpatient oncology dietician had previously been identified as a top barrier to care, according to a poster1 presented at the recent Association of Community Cancer Centers 40th National Oncology Conference.
“Head and neck cancer is not rare, but it is becoming more common, especially with HPV [human papillomavirus]–related head and neck cancers,” noted Joelle Hicks, BSN, RN, an oncology nurse navigator who presented the poster. “We had some difficulty with our processes for referral, so we wanted to work on simplifying that process.”
Not only is high-risk HPV increasingly causing oropharyngeal squamous cell carcinomas when it infect the mouth and throat, but it has also been shown to be the culprit of 70% of oropharyngeal cancers in the United States alone.2,3
According to the present research, there is a greater likelihood of nutritional deficit, lymphedema, depression, and anxiety among patients who have head and neck cancers. Therefore, benefits of early intervention referral to an oncology dietician include weight maintenance, decreased symptoms and AEs, and less time having to use a percutaneous endoscopic gastrostomy (PEG), or feeding, tube.
Initially, 60 patients were included in this analysis through automatic referral to an oncology dietician; ultimately, 41 were referred to dysphagia therapy. All had undergone radiation therapy in 2022 at the Summa Health Cancer Institute, and were referred within 3 months (n = 20) or 3 months or more (n = 21) of starting that treatment. A nutrition screening evaluated their usual body weight, if they did or did not have a recent weight change, whether they gained or lost weight, whether they noticed the weight change, food intake, symptoms in the last 2 weeks, diagnosis, and nutrition screening score.
Among those who participated within 3 months, all were considered to be at a normal or thin weight compared with 5 of the 21 who took 3 or more months to participate. Further in the latter group, 5 patients were on a modified diet and the remaining 11 could not take food in orally and had to use a PEG tube. The interventions they received included the following:
Hicks highlighted of her findings that streamlining the early referral process fostered a cohesive care team able to provide more individualized patient care, closer patient monitoring for recurrence with more touchpoints, and a higher level of trust among the care team. In turn, the team members found it easier to communicate with their patients regarding such issues as depression, anxiety, and financial distress. Further, overall cost of care dropped from the more frequent monitoring.
“When a recurrence is identified, it is identified much earlier and treatment is typically less invasive,” Hicks emphasized. “This leads to better outcomes and lower cost for the patient, as well as the organization.”
The 3 primary benefits she identified from this initiative were that building a more streamlined communication process into a solid infrastructure leads to greater continuity of care, early referral/intervention plus ongoing assessment from an oncology dietitian facilitates patient symptom management and prevention of unintended weight consequences, and early referral/intervention plus ongoing assessment from a speech and swallow therapist can better manage treatment-related symptoms and treatment AEs.
References
1. Hicks J. Proactive support interventions for head & neck cancer patients. Poster presented at: Association of Community Cancer Centers 40th National Oncology Conference; October 4-6, 2023; Austin, TX.
2. Husain N, Neyaz A. Human papillomavirus associated head and neck squamous cell carcinoma: controversies and new concepts. J Oral Biol Craniofac Res. 2017;7(3):198-205. doi:10.1016/j.jobcr.2017.08.003
3. HPV and oropharyngeal cancer. CDC. Updated September 12, 2023. Accessed October 17, 2023. https://tinyurl.com/nhfp6wvw
4. Hajdú SF, Wessel I, Dalton SO, Eskildsen SJ, Johansen C. Swallowing exercise during head and neck cancer treatment: results of a randomized trial. Dysphagia. 2022;37(4):749-762. doi:10.1007/s00455-021-10320-5
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discuss innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More